Status: Not yet recruiting
First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
ISH0688 is a human IgG1 Fc-FGF21 fusion protein. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of ISH0688 via subcutaneous injection.
Participants needed: 104
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: SUNHO（China）BioPharmaceutical CO., Ltd.Updated: Apr 1, 2026Locations: 1
Eligibility criteria
Not of childbearing potential: Including surgical sterilization performed at lea... [+16]
Undergo therapeutic lifestyle intervention during the lead-in period, maintain a... [+43]